Bernstein maintains RVMD at Market-Perform: clinical confidence rises after ASCO, but the stock price already reflects the main pancreatic cancer opportunity

Overview

This is a post-ASCO company research report by Bernstein on Revolution Medicines, Inc. The report focuses on RVMD's RAS(ON) inhibitor platform, especially the clinical opportunity for daraxonrasib in pancreatic ductal adenocarcinoma and non-small cell lung cancer. The core conclusion is that clinical confidence has increased, but the investment recommendation was not upgraded because the report believes the upside from pancreatic cancer revenue is already largely reflected in the current share price and valuation.

Core views

The report is positive on daraxonrasib's efficacy potential in KRAS-mutant PDAC and believes the first-line PDAC RASolute-303 trial has a high probability of success; however, RVMD's future revenue is highly concentrated in pancreatic cancer, so if RASolute-303 fails, the stock faces significant downside risk. The report also points out that randomized Phase III trials cannot be fully de-risked, and investors still need to apply a discount for clinical failure, intensifying competition, and real-world treatment duration falling short of assumptions.

Analysis framework

The report analyzes RVMD by combining clinical trial design, preliminary efficacy data, PDAC and NSCLC epidemiology, KRAS mutation subtype distribution, competing pipelines, commercial penetration assumptions, and DCF valuation. Key judgments include using the pharmaceutical industry's PTS framework to assess Phase III success probability, calibrating the revenue model using DOT relative to mPFS, estimating the addressable market using KRAS mutation epidemiology, and deriving a target price of 151.00 USD by discounting free cash flow through 2040.

Methodology notes

• Valuation methodsDCF

  discounted free cash flow

  The 151.00 USD target price is derived from a DCF model based on forecast free cash flow through 2040, using a WACC discount rate of 9.5%.

• Clinical probabilityPTS

  probability of technical success

  The report uses the pharmaceutical industry's standard PTS methodology to assess clinical success probability, and after ASCO it raised the PTS for RASolute-303 to 86%.

• Revenue modelingDOT and mPFS constraint

  treatment duration should not exceed median progression-free survival

  The report lowered the DOT assumption for 2L PDAC to 6.2 months and emphasized that real-world DOT is usually lower than mPFS because treatment practice, toxicity, and discontinuation rates shorten treatment duration.

• Market sizingEpidemiology and mutation distribution

  estimate market size using disease incidence, KRAS mutation rate, and lines of therapy

  The report uses KRAS mutation rates and subtype distributions in PDAC, CRC, NSCLC, and other cancers to assess the addressable market for RAS(ON) inhibitors.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Revolution Medicines, Inc. (RVMD.O)

  Covered company stock

  Strengths

  Has a differentiated RAS(ON) inhibitor platform, with a pipeline covering PDAC, NSCLC, and multiple KRAS mutation subtypes; cash reserves were significantly strengthened after financing.

  Weaknesses

  Revenue forecasts are highly concentrated in pancreatic cancer, the commercial model is sensitive to the outcomes of a few Phase III trials, and operating expense guidance was raised.

  Comparison

  Compared with earlier-stage pan-RAS and pan-KRAS competitors, RVMD has a more advanced clinical stage and potential first-mover advantage.

  Risks

  Phase III trial failure, insufficient durability of efficacy, real-world DOT below assumptions, intensifying competition, and valuation already reflecting success expectations in advance.

• daraxonrasib

  Core clinical asset and valuation driver

  Strengths

  As a multi-selective RAS(ON) inhibitor, it has entered multiple Phase III PDAC and NSCLC studies; preliminary 2L and 1L PDAC data support strong clinical confidence.

  Weaknesses

  Key revenue still depends on randomized Phase III validation such as RASolute-303, and the treatment duration assumption for 2L PDAC has been lowered.

  Comparison

  The report believes it may retain market leadership in KRAS-mutant PDAC and NSCLC, but competition in KRAS G12D is heating up.

  Risks

  RASolute-303 still carries about a 14% risk of failure, and efficacy may be uneven across different treatment lines, combination therapies, and subtypes.

• zoldonrasib

  KRAS G12D-selective pipeline asset

  Strengths

  Targets KRAS G12D, a highly prevalent subtype, and is planning first-line combination strategies in PDAC and NSCLC.

  Weaknesses

  The report believes its efficacy appears weaker than daraxonrasib, though its safety profile is cleaner and may make it better suited for combination therapy.

  Comparison

  The KRAS G12D space already has competitors such as HRS-4642 and INCB161734 showing preliminary activity, creating greater competitive pressure than in other non-G12C mutations.

  Risks

  If efficacy is insufficient or the combination strategy fails to differentiate, commercial penetration may be limited.

• NSCLC indication portfolio

  Subsequent market expansion opportunity

  Strengths

  RASolve-301 has evaluated 2/3L metastatic NSCLC, and a 1L NSCLC strategy is also being planned; non-G12C mutations may offer higher ROI.

  Weaknesses

  Details of the Phase III first-line NSCLC combination strategy are still pending company disclosure.

  Comparison

  Competition in G12C is concentrated and already includes approved drugs, while the non-G12C space is more unmet but also carries greater clinical development uncertainty.

  Risks

  Historical failure rates in later-line NSCLC trials are high, and combination design with immunotherapy or chemotherapy, endpoints, and the competitive landscape may all affect the probability of success.

Key data

• RatingMarket-PerformThe report maintains the rating unchanged, believing that revenue upside is already reflected in the stock price.
• Target price151.00 USDThe chart annotation indicates the target price corresponds to an expected return of about -3%.
• Risk-adjusted total revenue forecast14.5B USDThe report says that most of the portfolio's risk-adjusted revenue comes from pancreatic cancer.
• Pancreatic cancer revenue share83%About 12.1B USD of risk-adjusted revenue comes from pancreatic cancer, indicating high portfolio concentration.
• RASolute-303 PTS86%Raised after ASCO due to biomarker stratification, a lower chemotherapy control hurdle, and preliminary efficacy data.
• RASolute-303 indicated probability of failure~14%The report reminds readers that randomized Phase III trials cannot be fully de-risked.
• 2L PDAC DOT assumption6.2 monthsThis assumption is below the official mPFS of 7.2 months in the 2L PDAC dataset.
• DCF discount rate9.5% WACCUsed to calculate the 151.00 USD target price.
• 1Q26 cash and short-term investments1,908M USDThe report discloses the company's cash, cash equivalents, and short-term investments as of 1Q26.
• May 2026 cash position~4.4B USDEstimated cash level after the public offering, convertible bonds, and payment from Royalty Pharma.
• 2026 GAAP operating expense guidance1.7B-1.8B USDThe company raised its prior guidance of 1.6B-1.7B USD.
• US 2025 pancreatic cancer incidence and deaths67,440 new cases; 51,980 deathsThe report cites SEER data to show the high unmet need in PDAC.
• Estimated metastatic PDAC patients in 2026~49,000The report estimates the size of newly diagnosed metastatic PDAC patients in the US in 2026.
• KRAS mutation rate in PDAC~82%-92%Across different studies, PDAC has the highest proportion of KRAS mutations.

Impact & implications

For investors, RVMD's key issue is not a lack of clinical catalysts, but that valuation is overly dependent on daraxonrasib succeeding in PDAC. If RASolute-302 and RASolute-303 continue to validate efficacy, RVMD could obtain its first FDA label and strengthen the leadership position of its RAS(ON) platform; but if the first-line PDAC trial fails, valuation support would weaken significantly. The report therefore recommends staying neutral and waiting for further validation from key Phase III data and commercialization assumptions.

Risks

• If the first-line PDAC Phase III RASolute-303 fails, the report believes the market's core valuation logic for RVMD will face a major blow.
• Randomized Phase III trials cannot be fully de-risked; even if early data and readouts in other indications are positive, clinical failure risk remains.
• About 83% of portfolio revenue is concentrated in pancreatic cancer, and high indication concentration amplifies the impact of a single program's outcome on valuation.
• The DOT assumption for 2L PDAC has been lowered to 6.2 months; if real-world treatment duration is even shorter, revenue forecasts may be revised down further.
• Competition in KRAS G12D is intensifying, which may reduce market penetration for daraxonrasib or zoldonrasib in certain subtypes.
• The company's 2026 GAAP operating expense guidance was raised to 1.7B-1.8B USD, and cash burn and long-term profit margins still need to be monitored.
• The first-line NSCLC strategy is not yet fully clear, and there is still uncertainty around subsequent combination regimens, efficacy thresholds, and the competitive landscape.
• Safety, toxicity, discontinuation rates, and combination tolerability may affect real-world commercial performance.

What to watch

• Key data disclosure from RASolute-302 in 2L mPDAC and the potential FDA review pathway.
• Whether daraxonrasib can advance toward its first 2L PDAC label in 2026 through CNPV or other priority review mechanisms.
• Enrollment, event progression, and subsequent primary endpoint readout from the first-line PDAC RASolute-303 trial.
• DFS event progression in the adjuvant PDAC RASolute-304 study and key milestones around 2029.
• PFS and OS results from RASolve-301 in 2/3L NSCLC, as well as the company's first-line NSCLC registration strategy.
• Updates on ORR, durability of response, mPFS, and DOT for daraxonrasib in 1L PDAC.
• Efficacy and safety data from competing KRAS G12D pipelines such as HRS-4642, INCB161734, and GFH375/VS-7375.
• Early clinical progress of zoldonrasib, elironrasib, RMC-5127, and RM-055.
• Post-financing cash burn, changes in operating expense guidance, and long-term operating margin assumptions.